ARS Pharma Launches neffyinSchools to Improve Allergy Preparedness
Free neffy® nasal sprays are now available to K–12 schools to combat allergic emergencies.
.webp&w=1920&q=75&dpl=dpl_DvHKTkTrxtw9jHK6MpkEndZCmmr3)
ARS Pharmaceuticals, Inc., a biopharmaceutical leader focused on allergic reaction management, has unveiled the neffyinSchools program to empower K-12 schools across the U.S. The initiative provides eligible schools with two cartons of neffy® (epinephrine nasal spray) 2 mg, equating to four single-use doses, free of charge. Designed for emergency treatment of Type I Allergic Reactions, including anaphylaxis, neffy offers a needle-free solution for students weighing 66 lbs. or more. Replacement doses are also provided when the product is used or expires, ensuring schools are always prepared.
“School nurses are key to student health, and having accessible epinephrine is essential,” said Kenneth Mendez, CEO of the Asthma and Allergy Foundation of America. ARS Pharma’s Co-Founder and CEO, Richard Lowenthal, emphasized the device’s user-friendly design and the need for state legislative updates to support nasal epinephrine stocking in schools. A webinar for school nurses and administrators on this lifesaving program will be held on January 22, 2025.
Explore Neffy’s U.S. Launch – Needle-Free Allergy Protection
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Mehr aus Pharma News
Alle Beiträge →
Medicus Pharma reicht Phase‑2b/3‑Protokoll für Teverelix bei der FDA ein
Fresenius Kabi erhält FDA-Warnschreiben nach Fehlern bei der Untersuchung aseptischer Verarbeitung in der Anlage Melrose Park
Discussion